Showing results (151-160 of 162) with videos related to
Sort By:
Pageof 17
The New England Journal of Medicine|March 14, 2019
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related TuberculosisSusan Swindells, Ritesh Ramchandani, Amita Gupta, et al.Microbiology Spectrum|May 18, 2026
Effect of inhaled interferon-β1a on SARS-CoV-2 diversity and evolutionGregory E Edelstein, Tatum N Sass, Rinki Deo, et al.Nature Communications|August 22, 2022
Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19Kara W Chew, Carlee Moser, Eric S Daar, et al.JAMA Network Open|April 26, 2023
Safety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19: 2 Randomized Clinical TrialsRachel A Bender Ignacio, Kara W Chew, Carlee Moser, et al.Annals of Internal Medicine|April 17, 2023
Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19Teresa H Evering, Kara W Chew, Mark J Giganti, et al.Open Forum Infectious Diseases|September 22, 2025
Rapid Elimination of Culturable SARS-CoV-2 With Intramuscular or Intravenous Administration of Antiviral Monoclonal Antibody TherapyRinki Deo, Manish C Choudhary, Owen T Glover, et al.Medrxiv : the Preprint Server for Health Sciences|September 21, 2021
Emergence of SARS-CoV-2 Resistance with Monoclonal Antibody TherapyManish C Choudhary, Kara W Chew, Rinki Deo, et al.Nature Microbiology|October 27, 2022
Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trialManish C Choudhary, Kara W Chew, Rinki Deo, et al.Contemporary Clinical Trials|January 26, 2020
High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trialSusan E Dorman, Payam Nahid, Ekaterina V Kurbatova, et al.Nature Medicine|October 3, 2017
Defining total-body AIDS-virus burden with implications for curative strategiesJacob D Estes, Cissy Kityo, Francis Ssali, et al.Pageof 17